Portfolio company Silence acquired by Merck KGaA

IBT's portfolio sees a 130% premium exit as Silence is acquired for $20 per share.

What the company is saying

International Biotechnology Trust PLC (LSE:IBT) announces that its portfolio company Silence Therapeutics has signed a definitive agreement to be acquired by Merck KGaA. The release highlights that Silence shareholders will receive $20 per share in cash, a 130% premium over the 16 October closing price. IBT emphasizes the strategic value of its stock selection, noting that Silence represented 0.7% of IBT's Net Asset Value as of 16 October. Portfolio managers Ailsa Craig and Marek Poszepczynski frame the deal as part of a broader M&A wave driven by pharmaceutical companies seeking innovation ahead of major patent expiries. The managers assert that nine IBT portfolio companies have been acquired in 2026, matching the total for 2025, and position this as evidence of their selection process's effectiveness. The company states that the updated valuation for Silence will be reflected in IBT's NAV as of 19 October and reported on 20 October. The tone is confident, focusing on realised M&A activity and sector trends rather than speculative future gains.

What the data suggests

The acquisition of Silence Therapeutics at $20 per share delivers a 130% premium to its 16 October closing price, providing a clear and immediate value uplift for Silence shareholders. Silence accounted for 0.7% of IBT's Net Asset Value as of 16 October, so the direct impact on IBT's overall NAV will be modest but positive. The announcement confirms that nine IBT portfolio companies have been acquired in 2026, equaling the number in 2025, which supports the managers' claim of effective stock selection in a highly active M&A environment. The figures disclosed are specific and verifiable, but the release does not provide IBT's absolute NAV, realised gains, or broader portfolio performance metrics, limiting the ability to assess the overall financial trajectory. The sector commentary is supported by the number of acquisitions but is not quantified beyond that. The evidence is strongest for the Silence transaction itself, with less detail on IBT's aggregate performance.

Analysis

The announcement is factual and proportionate, with the main claims supported by concrete evidence: a definitive acquisition agreement for Silence Therapeutics, a specified $20 per share cash offer, and a quantified 130% premium. The only forward-looking statement is the routine update of IBT's NAV to reflect the new valuation, which is scheduled for the next business day and thus qualifies as immediate. There is no promotional or exaggerated language regarding future benefits, and no large capital outlay or delayed earnings impact is disclosed for IBT itself. The commentary on sector M&A trends and IBT's stock selection is positive but not overstated, and is supported by the disclosed number of portfolio acquisitions. The absence of broader profitability or NAV growth metrics means the signal cannot be strong_positive, but all claims about the Silence transaction are substantiated.

Risk flags

• ●The direct financial impact on IBT is limited by Silence's small weighting in the portfolio, representing only 0.7% of Net Asset Value as of 16 October. This means that even a 130% premium exit will not materially move the needle for overall NAV growth.
• ●The announcement does not disclose IBT's absolute NAV, realised gains from the Silence transaction, or broader portfolio performance, making it difficult for investors to assess the overall financial health or trajectory of the trust.
• ●Reliance on sector-wide M&A trends as a driver of value introduces risk if the current acquisition pace slows or if future deals do not command similar premiums, especially as the commentary suggests that structural drivers remain but does not quantify future pipeline.
• ●The update on the NAV impact of the Silence deal is pending and will only be available on 20 October, so investors do not yet have the precise effect of this transaction on IBT's reported figures.

Bottom line

IBT's announcement of Silence Therapeutics' acquisition by Merck KGaA delivers a 130% premium exit at $20 per share, but with Silence representing just 0.7% of IBT's NAV, the overall portfolio impact is modest. The deal is part of a broader trend, with nine IBT portfolio companies acquired in 2026, matching the previous year's total and supporting management's claims about effective stock selection in a hot M&A market. The figures around the Silence transaction are clear and immediate, with the NAV update due on 20 October, but the absence of absolute NAV or realised gain disclosures means investors cannot fully gauge the trust's aggregate performance. The sector commentary is well-supported by acquisition counts but lacks quantification of future value creation. Investors should focus on the upcoming NAV report for a concrete view of the transaction's impact, but should not expect a transformative effect given the small portfolio weighting. The most important takeaway is that IBT continues to benefit from sector M&A, but the magnitude of this particular exit is limited by position size.

Announcement summary

(LSE:IBT) International Biotechnology Trust PLC ("IBT") announced that its portfolio company Silence Therapeutics ("Silence") has entered into a definitive agreement to be acquired by Merck KGaA ("Merck"). Silence is a UK-based global clinical-stage biotechnology company developing precision engineered medicines using proprietary SiRNA (short interfering RNA) technology. The company's most advanced program is Divesiran, which has received FDA Fast Track and Orphan Drug designations for the treatment of polycythemia vera (PV), a rare form of blood cancer. Under the terms of the agreement, Silence shareholders will receive $20 per share in cash at closing. This represents a premium of approximately 130% to Silence's closing share price on 16 October. As at close of business on 16 October, Silence represented 0.7% of IBT's Net Asset Value, as included in IBT's daily NAV update on 19 October. Ailsa Craig and Marek Poszepczynski, portfolio managers of IBT, commented that the pharmaceutical sector continues to acquire biotech companies, with firms willing to pay significant premiums for innovative biotech businesses due to a historic wave of patent expiries in the coming years. IBT has seen nine portfolio companies acquired so far in 2026, matching the total for 2025. The managers stated that this demonstrates the effectiveness of IBT's stock selection process, which evaluates biotech companies through the same lens as potential acquirers. They also noted that the structural drivers of M&A remain firmly in place, and that the acquisitions seen this year only scratch the surface of the pharmaceutical sector's patent cliff. The updated valuation of IBT's holding in Silence will be included in IBT's NAV as at close of business on 19 October, to be reported in the usual way on 20 October.

Disagree with this article?